RenovoRx, Inc. (RNXT) shareholders
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30124% above fair value
$1.04−0.12 (-10.34%)
Close on Nov 13, 2026Market cap $46.93MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
20.4%
9M of 45M shares
Institutional holders
28
3 new, 6 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
13 buys · 0 sales
Net bought $84.49K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AIGH Capital Management LLC Joint filing with Orin Hirschman (9.80%) | 4,430,493 | 9.80% | 13G (passive) amendment | Mar 31, 2026 |
| AIGH Capital Management, LLC Joint filing with Hirschman Orin (9.50%) | 3,467,275 | 9.50% | 13G (passive) | Mar 31, 2025 |
| Orin Hirschman Joint filing with AIGH Capital Management LLC (7.10%) | 2,615,193 | 7.10% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNXT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | 9.76% | $4.32M | +699,242 | 0.27% |
| Bleichroeder LP | 1,666,098 | 3.69% | $1.63M | – | 0.29% |
| Vanguard Capital Management LLC | 1,443,742 | 3.20% | $1.41M | −3,435 | 0.00% |
| Geode Capital Management, LLC | 424,148 | 0.94% | $415.69K | +42,425 | 0.00% |
| Wealthspire Advisors, LLC | 252,525 | 0.56% | $247.48K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 240,330 | 0.53% | $235.52K | +82,428 | 0.00% |
| Citadel Advisors LLC | 133,597 | 0.30% | $130.93K | −99,087 | 0.00% |
| Chicago Partners Investment Group LLC | 92,356 | 0.20% | $78.92K | – | 0.00% |
| Northern Trust Corp | 85,207 | 0.19% | $83.50K | +43,046 | 0.00% |
| Northwestern Mutual Wealth Management Co | 74,596 | 0.17% | $73.10K | −24,864 | 0.00% |
| Caprock Group, LLC | 63,940 | 0.14% | $62.66K | – | 0.00% |
| Jane Street Group, LLC | 46,399 | 0.10% | $45.47K | +22,262 | 0.00% |
| Kestra Advisory Services, LLC | 35,520 | 0.08% | $34.81K | – | 0.00% |
| Two Sigma Securities, LLC | 34,788 | 0.08% | $34.09K | +16,892 | 0.00% |
| XTX Topco Ltd | 29,983 | 0.07% | $29.38K | −528 | 0.00% |
| Clear Creek Financial Management, LLC | 29,058 | 0.06% | $28.48K | New | 0.00% |
| State Street Corp | 26,152 | 0.06% | $25.63K | – | 0.00% |
| UBS Group AG | 20,820 | 0.05% | $20.40K | +17,482 | 0.00% |
| HighTower Advisors, LLC | 20,000 | 0.04% | $19.60K | – | 0.00% |
| Cetera Investment Advisers | 19,000 | 0.04% | $18.62K | +1,000 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 9M | 20.4% | 3 / 8 | 6 / 6 | 1M | 0M |
| Q1 2026 | 31 | 9M | 19.0% | 4 / 11 | 4 / 5 | 4M | 0M |
| Q4 2025 | 33 | 7M | 14.6% | 8 / 8 | 7 / 6 | 1M | 1M |
| Q3 2025 | 31 | 7M | 15.8% | 8 / 5 | 6 / 2 | 0M | 2M |
| Q2 2025 | 25 | 9M | 19.5% | 5 / 4 | 4 / 7 | 1M | 2M |
| Q1 2025 | 27 | 10M | 22.3% | 13 / 7 | 2 / 4 | 9M | 0M |
| Q4 2024 | 18 | 1M | 2.2% | 6 / 3 | 3 / 1 | 0M | 1M |
| Q3 2024 | 13 | 2M | 4.2% | 2 / 3 | 3 / 5 | 1M | 0M |
| Q2 2024 | 17 | 1M | 2.0% | 8 / 4 | 1 / 1 | 1M | 0M |
| Q1 2024 | 10 | 0M | 0.7% | 0 / 5 | 1 / 2 | 0M | 0M |
| Q4 2023 | 12 | 0M | 0.7% | 4 / 3 | 1 / 6 | 0M | 0M |
| Q3 2023 | 14 | 0M | 0.8% | 5 / 3 | 2 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held RNXT in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RNXT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,034,193 | 2.29% | $1.01M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 379,921 | 0.84% | $372.32K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 178,391 | 0.40% | $162.23K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 77,982 | 0.17% | $70.92K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 49,555 | 0.11% | $45.07K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 29,628 | 0.07% | $29.04K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 20,477 | 0.05% | $18.62K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ramtin Agah | Chief Medical Officer, Director | 1,773,460 | 3.93% | Apr 7, 2026 |
| Shaun Bagai | Chief Executive Officer, Director | 364,340 | 0.81% | Apr 7, 2026 |
| Mark Voll | Chief Financial Officer | 319,580 | 0.71% | Sep 15, 2026 |
| Leesa Gentry | Chief Clinical Officer | – | – | Apr 7, 2026 |
| Ron Kocak | VP, Controller and PAO | 12,595 | 0.03% | Jul 3, 2025 |
| K. Angela Macfarlane | Director | 40,983 | 0.09% | Oct 2, 2026 |
| Laurence Marton | Director | 75,884 | 0.17% | Oct 2, 2026 |
| Una S. Ryan | Director | 80,959 | 0.18% | Oct 2, 2026 |
| Robert J. Spiegel | Director | 40,983 | 0.09% | Oct 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Voll Chief Financial Officer | Sep 10, 2026 | Award | +80,000 | – | – | 222,380 |
| Mark Voll Chief Financial Officer | May 19, 2026 | Buy | +25,000 | $0.79 | $19.75K | 142,380 |
| Mark Voll Chief Financial Officer | Apr 3, 2026 | Award | +80,000 | – | – | 117,380 |
| Mark Voll Chief Financial Officer | Mar 25, 2026 | Award | +12,380 | – | – | 37,380 |
| Laurence Marton Director | Mar 20, 2026 | Buy | +9,720 | – | – | 9,720 |
| Mark Voll Chief Financial Officer | Mar 20, 2026 | Buy | +97,200 | – | – | 97,200 |
| Shaun Bagai Chief Executive Officer, Director | Mar 20, 2026 | Buy | +24,300 | – | – | 313,357 |
| Ramtin Agah Chief Medical Officer, Director | Jan 21, 2026 | Buy | +10,000 | $1.00 | $10.00K | 798,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 31, 2025 | Buy | +9,795 | $0.86 | $8.42K | 788,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 30, 2025 | Buy | +205 | $0.83 | $170 | 778,665 |
| Shaun Bagai Chief Executive Officer, Director | Dec 18, 2025 | Buy | +5,000 | $0.90 | $4.50K | 340,040 |
| Shaun Bagai Chief Executive Officer, Director | Dec 17, 2025 | Buy | +5,000 | $0.85 | $4.25K | 335,040 |
| Ramtin Agah Chief Medical Officer, Director | Dec 16, 2025 | Buy | +12,000 | $0.85 | $10.20K | 778,460 |
| Ramtin Agah Chief Medical Officer, Director | Dec 5, 2025 | Buy | +10,000 | $0.96 | $9.60K | 766,460 |
| Ramtin Agah Chief Medical Officer, Director | Nov 24, 2025 | Buy | +12,000 | $0.80 | $9.60K | 756,460 |
| Ramtin Agah Chief Medical Officer, Director | Nov 21, 2025 | Buy | +10,000 | $0.80 | $8.00K | 744,460 |
| Shaun Bagai Chief Executive Officer, Director | Aug 25, 2025 | Buy | +5,000 | $0.91 | $4.55K | 330,040 |
| Shaun Bagai Chief Executive Officer, Director | Aug 22, 2025 | Buy | +5,000 | $0.95 | $4.75K | 325,040 |
| Ramtin Agah Chief Medical Officer, Director | Jun 5, 2025 | Buy | +21,000 | $1.40 | $29.40K | 734,460 |
| Laurence Marton Director | May 2, 2025 | Option exercise | +20,480 | $0.15 | $3.07K | 66,164 |
| Ramtin Agah Chief Medical Officer, Director | Apr 22, 2025 | Gift | −400,000 | – | – | 713,460 |
| Ramtin Agah Chief Medical Officer, Director | Apr 15, 2025 | Buy | +15,000 | $0.90 | $13.50K | 1,113,460 |
| Shaun Bagai Chief Executive Officer, Director | Apr 15, 2025 | Buy | +7,500 | $0.91 | $6.83K | 320,040 |
| Ramtin Agah Chief Medical Officer, Director | Apr 11, 2025 | Buy | +20,000 | $0.80 | $16.00K | 1,098,460 |
| Ron Kocak VP Controller and PAO | Apr 10, 2025 | Buy | +6,500 | $0.79 | $5.14K | 12,595 |
| Shaun Bagai Chief Executive Officer, Director | Apr 9, 2025 | Buy | +10,000 | $0.83 | $8.30K | 312,540 |
| Ron Kocak VP Controller and PAO | Apr 9, 2025 | Buy | +6,000 | $0.80 | $4.80K | 6,095 |
| Ramtin Agah Chief Medical Officer, Director | Apr 9, 2025 | Buy | +30,000 | $0.81 | $24.30K | 1,078,460 |
| Ron Kocak VP Controller and PAO | Apr 8, 2025 | Buy | +95 | $0.80 | $76 | 95 |
| Laurence Marton Director | Apr 8, 2025 | Buy | +12,050 | $0.85 | $10.24K | 45,684 |
| Ramtin Agah Chief Medical Officer, Director | Apr 8, 2025 | Buy | +26,000 | $0.84 | $21.84K | 1,048,460 |
| Shaun Bagai Chief Executive Officer, Director | Apr 7, 2025 | Buy | +10,000 | $0.83 | $8.30K | 302,540 |
| Robert J. Spiegel Director | Jan 26, 2024 | Buy | +40,983 | – | – | 40,983 |
| Ramtin Agah Chief Medical Officer, Director | Jan 26, 2024 | Buy | +40,983 | – | – | 47,460 |
| Laurence Marton Director | Jan 26, 2024 | Buy | +8,196 | – | – | 33,634 |
| K. Angela Macfarlane Director | Jan 26, 2024 | Buy | +40,983 | – | – | 40,983 |
| Shaun Bagai Chief Executive Officer, Director | Jan 26, 2024 | Buy | +40,983 | – | – | 292,540 |
| Angela Nelms Chief Operating Officer | Oct 3, 2023 | Buy | +300 | $1.05 | $315 | 300 |
| Angela Nelms Chief Operating Officer | Oct 3, 2023 | Buy | +800 | $1.05 | $840 | 1,100 |
| Laurence Marton Director | Nov 3, 2022 | Option exercise | +25,438 | $1.70 | $43.24K | 25,438 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Jun 7, 2022 | Buy | +5,182 | $1.93 | $10.00K | 6,477 |
| Shaun Bagai Chief Executive Officer, Director | May 19, 2022 | Buy | +5,500 | $2.05 | $11.27K | 251,557 |
| Una S. Ryan Director | Apr 22, 2022 | Other | +26,838 | $0.93 | $24.96K | 80,959 |
| Una S. Ryan Director | Apr 22, 2022 | Other | +16,206 | $1.62 | $26.25K | 97,165 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Mar 16, 2022 | Gift | +975,000 | – | – | 975,000 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Mar 16, 2022 | Gift | −975,000 | – | – | 1,295 |
| Una S. Ryan Director | Mar 3, 2022 | Other | +6,332 | $3.95 | $25.01K | 54,121 |
| Una S. Ryan Director | Mar 3, 2022 | Other | +47,789 | $4.19 | $200.24K | 47,789 |
| Ramtin Agah Chief Medical Officer, Director, 10% owner | Aug 30, 2021 | Conversion | +1,295 | – | – | 976,295 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.35%
1M shares short
Days to cover
3.5
At 0M shares a day
Change since last report
+15.4%
From 1M shares
Short volume, 20 days
60.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of RenovoRx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,251 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?